{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:33:40Z","timestamp":1792514020095,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:sec>\n            <jats:title>Backgrounds:<\/jats:title>\n            <jats:p>Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs. Although some studies compared the efficacies of treatment switch from ETV to TAF, there has been no randomized study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed a prospective multicenter randomized controlled study in which subjects were enrolled from April 2018 to June 2019 and observed for 2 years until March 2021 to clarify the efficacy and safety of switching from ETV to TAF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirty-three patients were enrolled and randomized into 2 groups, and a total of 30 patients were evaluated; a TAF-switching group (n\u2005=\u200516) and an ETV-continuing group (n\u2005=\u200514). The mean age of the 30 patients was 61 years old and 18 patients (60%) were male. The serum HBV DNA in all patients were below detection limit. The mean change in hepatitis B surface antigen (HBsAg) levels after 2 years was not significantly different between the TAF and ETV groups (\u20130.08 vs \u20130.20 log IU\/mL, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.07). Comparing the group with a HBsAg decline (\u2264 \u20130.1 log IU\/mL) and a group without a HBsAg decline in an overall analysis, the prior ETV duration was significantly shorter in the HBsAg-declined group (49 vs 92 months, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.03). Although the eGFR levels tended to decrease in the TAF group compared to ETV (\u20136.15 vs \u20132.26\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.09), no significant differences were observed in patients with baseline eGFR\u2005&lt;\u200560 (\u20132.49 vs 0.40\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.25).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The efficacy and safety were comparable in the TAF-switching group and the ETV-continuing group. Because the present study was conducted in limited patients, a larger study will be required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030630","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T14:17:01Z","timestamp":1664547421000},"page":"e30630","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study"],"prefix":"10.1097","volume":"101","author":[{"given":"Kosuke","family":"Sato","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-7835","authenticated-orcid":false,"given":"Jun","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Akahane","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tohoku Rosai Hospital, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, Kurihara Central Hospital, Kurihara, Miyagai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kisara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Japan Community Health Care Organization Sendai Minami Hospital, Sendai, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Iwata","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Sano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Tsuruoka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masazumi","family":"Onuki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.29785","article-title":"Cellular membrane trafficking machineries used by the hepatitis viruses.","volume":"68","author":"Inoue","year":"2018","journal-title":"Hepatology"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited.","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/v13061124","article-title":"Envelope proteins of hepatitis B virus: molecular biology and involvement in carcinogenesis.","volume":"13","author":"Inoue","year":"2021","journal-title":"Viruses"},{"issue":"Suppl S1","key":"R8-20250504","first-page":"1","article-title":"JSH guidelines for the management of hepatitis B virus infection.","volume":"44","year":"2014","journal-title":"Hepatol Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00535-018-1502-y","article-title":"Long-term outcome of entecavir treatment of nucleos(t)ide analogue-na\u00efve chronic hepatitis B patients in Japan.","volume":"54","author":"Suzuki","year":"2019","journal-title":"J Gastroenterol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hepr.12902","article-title":"Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-na\u00efve chronic hepatitis B patients.","volume":"48","author":"Koike","year":"2018","journal-title":"Hepatol Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.","volume":"64","author":"Arends","year":"2015","journal-title":"Gut"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest.","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MEG.0000000000001733","article-title":"Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.","volume":"32","author":"Kumada","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jmv.25644","article-title":"Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.","volume":"92","author":"Uchida","year":"2020","journal-title":"J Med Virol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jgh3.12443","article-title":"Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B.","volume":"5","author":"Itokawa","year":"2021","journal-title":"JGH Open"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/hepr.13650","article-title":"Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: long-term effects from a prospective study.","volume":"51","author":"Hagiwara","year":"2021","journal-title":"Hepatol Res"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.14309\/ajg.0000000000001157","article-title":"Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir.","volume":"116","author":"Nguyen","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep.30956","article-title":"Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection.","volume":"71","author":"Murata","year":"2020","journal-title":"Hepatology"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3892\/br.2020.1396","article-title":"Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: a pilot randomized controlled study.","volume":"14","author":"Inoue","year":"2021","journal-title":"Biomed Rep"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12072-016-9734-5","article-title":"Molecular mechanisms of HBeAg in persistent HBV infection.","volume":"11","author":"Chen","year":"2017","journal-title":"Hepatol Int"},{"key":"R25-20250504","first-page":"1696","article-title":"HBV secretion is regulated through the activation of endocytic and autophagic compartments mediated by Rab7 stimulation.","volume":"128","author":"Inoue","year":"2015","journal-title":"J Cell Sci"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2013.01.028","article-title":"Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-na\u00efve, e antigen-positive patients.","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J Hepatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/jgh.12304","article-title":"Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers.","volume":"28","author":"Xun","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jmv.25515","article-title":"Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.","volume":"91","author":"Hagiwara","year":"2019","journal-title":"J Med Virol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/hepr.13399","article-title":"Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.","volume":"49","author":"Suzuki","year":"2019","journal-title":"Hepatol Res"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3851\/IMP2761","article-title":"Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.","volume":"19","author":"Ezinga","year":"2014","journal-title":"Antivir Ther"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/ijms21030949","article-title":"Novel biomarkers of hepatitis B and hepatocellular carcinoma: clinical significance of HBcrAg and M2BPGi.","volume":"21","author":"Baudi","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:16:40Z","timestamp":1746335800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":32,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030630","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}